Alkermes Plc
NASDAQ:ALKS

Watchlist Manager
Alkermes Plc Logo
Alkermes Plc
NASDAQ:ALKS
Watchlist
Price: 28.78 USD 3.9% Market Closed
Market Cap: 4.7B USD
Have any thoughts about
Alkermes Plc?
Write Note

Alkermes Plc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Alkermes Plc
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Alkermes Plc
NASDAQ:ALKS
Revenue
$1.5B
CAGR 3-Years
10%
CAGR 5-Years
7%
CAGR 10-Years
10%
Amarin Corporation PLC
NASDAQ:AMRN
Revenue
$241m
CAGR 3-Years
-26%
CAGR 5-Years
-8%
CAGR 10-Years
18%
Prothena Corporation PLC
NASDAQ:PRTA
Revenue
$133.4m
CAGR 3-Years
-13%
CAGR 5-Years
178%
CAGR 10-Years
11%
No Stocks Found

Alkermes Plc
Glance View

Market Cap
4.7B USD
Industry
Biotechnology

Alkermes Plc is a global biopharmaceutical company. The company is headquartered in Dublin, Dublin and currently employs 2,211 full-time employees. The firm is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The company has a portfolio of commercial products focused on addiction, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurodegenerative disorders and cancer. The firm's products include ALKERMES, ARISTADA, ARISTADA INITIO, LinkeRx, LYBALVI, NanoCrystal and VIVITROL. Its other trademark includes INVEGA SUSTENNA, INVEGA TRINZA, TREVICTA, XEPLION, and RISPERDAL CONSTA, KEYTRUDA and VUMERITY. The firm's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.

ALKS Intrinsic Value
28.59 USD
Overvaluation 1%
Intrinsic Value
Price

See Also

What is Alkermes Plc's Revenue?
Revenue
1.5B USD

Based on the financial report for Sep 30, 2024, Alkermes Plc's Revenue amounts to 1.5B USD.

What is Alkermes Plc's Revenue growth rate?
Revenue CAGR 10Y
10%

Over the last year, the Revenue growth was -5%. The average annual Revenue growth rates for Alkermes Plc have been 10% over the past three years , 7% over the past five years , and 10% over the past ten years .

Back to Top